Cargando…

Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals

BACKGROUND: Clearance of hepatitis C virus (HCV) can potentially slow or reverse liver fibrosis and cirrhosis. Studies of fibrosis changes after treatment with direct-acting antivirals (DAAs) are limited. OBJECTIVES: We aimed to assess the impact of DAAs on fibrosis in HCV treatment responders. DESI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alswat, Khalid, Al-Sohaibani, Fahad, Khathlan, Abdullah, Bashmail, Ahmad, Alanazi, Mohammed, Kurdi, Amr, Almakadma, Abdul Hakim, Al-hamoudi, Waleed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	King Faisal Specialist Hospital and Research Centre 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981998/ https://www.ncbi.nlm.nih.gov/pubmed/35380056 http://dx.doi.org/10.5144/0256-4947.2022.89

Ejemplares similares

Validation of the EVendo score for the prediction of varices in cirrhotic patients
por: Alswat, Khalid, et al.
Publicado: (2022)

Surface Gene Variants of Hepatitis B Virus in Saudi Patients
por: Al-Qudari, Ahmed Y., et al.
Publicado: (2016)

Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals
por: Tufan, Ayse Gokcen, et al.
Publicado: (2020)

SASLT practice guidelines for the management of Hepatitis B virus – An update
por: Abaalkhail, Faisal A., et al.
Publicado: (2021)

The Saudi Association for the Study of Liver Diseases and Transplantation clinical practice guidelines for management of autoimmune hepatitis
por: Aljumah, Abdulrahman A., et al.
Publicado: (2018)

SASLT Position Statement on the Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection
por: Alghamdi, Abdullah S., et al.
Publicado: (2015)

A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity
por: Nguyen, Henry H., et al.
Publicado: (2018)

Correlation Between Hepatitis B Surface Antigen Titers and HBV DNA Levels
por: Alghamdi, Amal, et al.
Publicado: (2013)

Hepatitis B Management: It Is Time to Change the Strategy
por: Al-hamoudi, Waleed K.
Publicado: (2014)

Hepatic vasculitis mimicking liver abscesses in a patient with systemic lupus erythematosus
por: Alanazi, Thari, et al.
Publicado: (2009)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Management of Hepatitis C Genotype 4 in the Liver Transplant Setting
por: Al-hamoudi, Waleed K.
Publicado: (2016)

Regression in hepatic fibrosis in elderly Chinese patients with hepatitis C receiving direct-acting antiviral treatment
por: Niu, Bin, et al.
Publicado: (2023)

Hepatoprotective and Antiviral Efficacy of Acacia mellifera Leaves Fractions against Hepatitis B Virus
por: Arbab, Ahmed H., et al.
Publicado: (2015)

Diminished accuracy of biomarkers of fibrosis in low replicative chronic hepatitis B
por: Sanai, Faisal M., et al.
Publicado: (2017)

Complementary and alternative medicine use and its association with medication adherence in inflammatory bowel disease and other gastrointestinal diseases
por: Almakadma, Abdul Hakim, et al.
Publicado: (2023)

The Correlation Between Hepatitis B Virus Precore/Core Mutations and the Progression of Severe Liver Disease
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2018)

Association between HLA Variations and Chronic Hepatitis B Virus Infection in Saudi Arabian Patients
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2014)

Direct-Acting Antiviral Treatment in Albanian Patients With Chronic Hepatitis C and Advanced Liver Fibrosis
por: Cuko, Liri, et al.
Publicado: (2022)

Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease burden – Saudi Arabia and United Arab Emirates, 2017–2030
por: Alswat, Khalid, et al.
Publicado: (2018)

Influence of some methylated hepatocarcinogenesis-related genes on the response to antiviral therapy and development of fibrosis in chronic hepatitis C patients
por: Mostafa, Waleed Seif Eldin Mohamed, et al.
Publicado: (2020)

Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C
por: Abdulla, Maheeba, et al.
Publicado: (2022)

Correlation between Genetic Variations and Serum Level of Interleukin 28B with Virus Genotypes and Disease Progression in Chronic Hepatitis C Virus Infection
por: Al-Qahtani, Ahmed, et al.
Publicado: (2015)

IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection
por: Abdo, Ayman A., et al.
Publicado: (2013)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients
por: Mölleken, Christian, et al.
Publicado: (2019)

Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct‐Acting Antivirals for Hepatitis C
por: Pan, Jason J., et al.
Publicado: (2018)

M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals
por: Saleh, Shereen A, et al.
Publicado: (2020)

Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C
por: Aggeletopoulou, Ioanna, et al.
Publicado: (2017)

SASLT Practice Guidelines for the Management of Hepatitis B Virus
por: Abaalkhail, Faisal, et al.
Publicado: (2014)

Hepatitis B virus (HBV) X gene mutations and their association with liver disease progression in HBV-infected patients
por: Al-Qahtani, Ahmed A., et al.
Publicado: (2017)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Soriano, Vicente, et al.
Publicado: (2022)

Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis
por: Wellington, Jennifer, et al.
Publicado: (2021)

Fibrosis regression following hepatitis C antiviral therapy
por: Elsharkawy, Aisha, et al.
Publicado: (2022)

Effect of Interferon Treatment on Hearing of Patients with Chronic Hepatitis C
por: Hagr, Abdulrahman, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kk5l5hnr5iiq39o4iu4uckr978